ACADIA Pharmaceuticals (NASDAQ:ACAD) Announces Quarterly Earnings Results

ACADIA Pharmaceuticals (NASDAQ:ACAD) announced its earnings results on Wednesday. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.11, FiscalAI reports. ACADIA Pharmaceuticals had a return on equity of 9.12% and a net margin of 30.13%. The business had revenue of $342.30 million for the quarter, compared to analysts’ expectations of $332.58 million. During the same period last year, the firm posted $0.42 earnings per share. The business’s revenue for the quarter was up 22.8% on a year-over-year basis.

Here are the key takeaways from ACADIA Pharmaceuticals’ conference call:

• ACADIA reported $342 million in Q3 revenue, up 22% year over year on an adjusted basis. DAYBUE sales reached a record $140 million, up 39%, while NUPLAZID generated $202 million, up 12%; growth for both brands was largely volume-driven.
• ACADIA raised its 2026 DAYBUE sales guidance to $505 million–$520 million, citing STIX momentum, with more than half of U.S. patients using the formulation by quarter-end. The company also highlighted its Germany launch and a newly allowed U.S. patent expected to protect both formulations through March 2041, while reiterating its $700 million sales ambition for 2028.
• NUPLAZID guidance was narrowed to $760 million–$775 million, with management citing the time needed for its expanded sales force to build prescribing relationships. ACADIA maintained its ambition of approximately $1 billion in NUPLAZID sales by the end of 2028.
• The phase II RADIANT trial of remlifanserin in Alzheimer’s disease psychosis narrowly missed statistical significance on its primary endpoint (p=0.0603), although the 60 mg dose showed activity across four efficacy scales and a nominally significant result on a key secondary endpoint. ACADIA plans to advance the 60 mg dose and adjust trial conduct and statistical methods for phase III; the primary endpoint remains unchanged.
• ACADIA expects phase II results for remlifanserin in Lewy body dementia psychosis and for ACP-211 in major depressive disorder in the second half of 2027, extending the timeline for pipeline updates. The company ended the quarter with $976 million in cash.

ACADIA Pharmaceuticals Trading Up 0.2%

Shares of ACAD stock traded up $0.04 on Friday, reaching $21.28. The company’s stock had a trading volume of 710,284 shares, compared to its average volume of 1,746,589. The stock’s fifty day simple moving average is $23.03 and its 200-day simple moving average is $23.62. ACADIA Pharmaceuticals has a 1 year low of $18.39 and a 1 year high of $30.96. The company has a market capitalization of $3.67 billion, a price-to-earnings ratio of 10.09 and a beta of 0.87.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ACAD. Weiss Ratings upgraded shares of ACADIA Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, August 12th. Wall Street Zen lowered ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday. UBS Group downgraded ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $49.00 to $23.00 in a research report on Tuesday, October 13th. Oppenheimer reissued a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Wednesday, September 23rd. Finally, Royal Bank Of Canada raised their price objective on ACADIA Pharmaceuticals from $36.00 to $38.00 and gave the stock an “outperform” rating in a research note on Thursday. Thirteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $31.45.

Insider Activity at ACADIA Pharmaceuticals

In other news, EVP Mark Schneyer sold 3,321 shares of the company’s stock in a transaction dated Friday, October 30th. The shares were sold at an average price of $20.88, for a total transaction of $69,342.48. Following the sale, the executive vice president directly owned 71,322 shares in the company, valued at approximately $1,489,203.36. This represents a 4.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 26.20% of the stock is owned by insiders.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system and neuropsychiatric disorders. The company’s research programs target conditions with significant unmet medical needs, including neurological and rare neurodevelopmental diseases.

ACADIA’s commercial products include NUPLAZID (pimavanserin), an atypical antipsychotic approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis.